CIBMTR® A RESEARCH COLLABORATION BETWEEN THE MEDICAL COLLEGE OF WISCONSIN AND NMOP

Thalassemia Post-Infusion Data

Registry Use Only	
Sequence Number:	
Date Received:	
CIBMTR Center Number:	
CIBMTR Research ID:	
Event date:	
YYYY MM DD	
Visit	
☐ 100 day ☐ 6 months	
☐ 1 year	
☐ 1 year ☐ 2 years ☐ > 2 years, Specify:	

CIBMTR Center Number:		ter Number: CIBMTR Research ID:
Report	all find	dings SINCE DATE OF LAST REPORT unless otherwise specified
Post-In	nfusior	n Disease Testing
		emoglobin electrophoresis performed? (do not include results if an RBC transfusion occurred within 4 of the electrophoresis study)
		Yes – Go to question 2
		No – Go to question 16
		Not applicable (transfused within 4 weeks) – Go to question 16
		Unknown – Go to question 16
	2.	Date of most recent electrophoresis:
;	Specif	y the hemoglobin allele types based on the sample tested above
	3.	Hb A
		☐ Yes – Go to question 4
		□ No – Go to question 5
		4. Hb A: %
	5.	Hb A2
		☐ Yes – Go to question 6
		□ No – Go to question 7
		6. Hb A2: %
	7.	Hb C
		☐ Yes – Go to question 8
		□ No – Go to question 9
		8. Hb C: %
	9.	Hb F
		☐ Yes – Go to question 10
		□ No – Go to question 11
		10. Hb F: %

CIBMTR Center Number:	CIBMTR Research ID:
11. Hb E	
□ Yes – G	to to question 12
□ No – G o	to question 13
12. Hb E:	%
13. Other thalass	semia related hemoglobin allele type
☐ Yes- Go	to question 14
□ No – G o	o to question 16
14. Speci	fy:
15. Level:	<u> </u>
Transfusion Therapy	
16. Were any red blood	cell (RBC) transfusions administered?
☐ Yes- Go to que	estion 17
□ No – Go to qu	estion 18
17. Date of last tr	ransfusion:
17. Date of last ti	YYYY MM DD
Treatment	
40 14 11 11 1	
18. Was the recipient o	
☐ Yes – Go to	
□ No – Go to q	
□ Unknown – G	to to question 24
19. Was iron che	elation previously reported?
□ Yes – G	to to question 22
□ No - G o	o to question 20
	started
	own - Go to question 21
□ Un	known - Go to question 22
21.	Date started: Date estimated
	YYYY MM DD

CIBM	ITR C	enter	Number:	CIBM	TR Research II	D:	
	22.	ls i	ron chelation ongoing?				
			Yes - Go to question 24	Į.			
			No – Go to question 23				
		23.	Date of last dose:				Date estimated
				YYYY	MM	DD	<u> </u>
24.	Was	s phlek	ootomy performed?				
		Yes -	- Go to question 25				
		No –	Go to question 30				
	25.	Wa	s phlebotomy previously re	eported?			
			Yes - Go to question 28	}			
			No - Go to question 26				
		26.	Date started				*
			☐ Known - Go to ques	stion 27			
			☐ Unknown - Go to qu	uestion 28			
			27. Date started:				Date estimated
				YYYY	MM	DD	
	28.	ls p	phlebotomy ongoing?				
			Yes - Go to question 30				
			No – Go to question 29				
		29.	Date completed:				Date estimated
				YYYY	MM	DD	
Spler	nic As	sessn	nents				
30.	Did	the re	cipient have a splenectomy	/?			
		Yes -	Go to question 32				
		No –	Go to question 31				
		Not a	pplicable (prior splenector	ny previously r	eported) - Go t	o question 3	32
		Unkn	own – Go to question 31				
	31.	Did	the recipient have splenor	megaly?			
			Yes				

CIBIN	IIK	Center Number: CIBMTR Research ID:
		□ No
Нера	tic A	ssessments
32.	Do	es the recipient have hepatomegaly? (≥ 2 cm below costal margin)
		Yes- Go to question 33
		No- Go to question 35
		Unknown– Go to question 35
	33.	Is liver size known?
		□ Yes – Go to question 34
		□ No – Go to question 35
	34.	Liver size as measured below the right costal margin at most recent evaluation: cm
35.	Wa	as liver iron content (LIC) tested?
		Yes – Go to question 36
		No – Go to question 38
	36.	
		□ g Fe/kg liver dry weight
		□ µmol Fe/g liver dry weight
	37.	Method used to estimate LIC?
		☐ T2*MRI (T2* weighted magnetic resonance imaging)
		□ SQUID MRI
		□ FerriScan
		☐ Liver biopsy
		□ Other
38.	Wa	as a liver biopsy performed?
		Yes – Go to questions 39
		No – Go to questions 46
	39.	Date assessed
	JJ.	☐ Known – Go to question 40
		☐ Unknown – Go to question 41
		40. Date assessed: Date estimated

CIBMTR Center Number:			CIBMTR Research ID:			
				YYYY	MM	DD
41.	Was	s there	evidence of li	ver cirrhosis?		
		Yes				
		No				
		Unk	nown			
42.	Was	s there	evidence of li	ver fibrosis?		
		Yes –	Go to questi	on 43		
		No – G	Go to questio	n 44		
		Unkno	wn – Go to q	uestion 44		
	43.	Туре	e of fibrosis			
			Bridging			
			Periportal			
			Other			
			Unknown			
44.	Was	s there	evidence of c	hronic hepatitis	?	
		Yes				
		No				
		Unkno	wn			
45.	ls d	ocumer	ntation being	attached? (CIBI	MTR recommer	nds attaching the liver biopsy report)
		Yes				
		No				
Labo	orator	y studi	es.			
46. Total	serur	n bilirul	oin			
	(nown	– Go t	to question 4	17		
_ L	Jnkno	wn – G	o to question	n 49		
47.	Tota	al serun	n bilirubin:	•	_ □ mg/dL	
					□ µmol/L	
48.	Upp	er limit	of normal for	your institution	:•	•

CIBMTR Form 2158 R2 (6 - 14). Form Released 26 July 2024. Last Updated 26 July 2024. Copyright $^{\tiny \odot}$ 2024 The Medical College of Wisconsin, Inc and NMDP. All rights reserved.

49.

Direct bilirubin

CIBM	ITR Cer	nter Number: 0	CIBMTR Research ID:
	□ К	nown – Go to question 50	
	□ U	nknown – Go to question 52	
	50.	Direct bilirubin: ●	□ mg/dL □ μmol/L
	51.	Upper limit of normal for your institution	n:•
52.	AST (SGOT)	
	,	own – Go to question 53	
		known – Go to question 54	
	<u> Б</u> 0П	Known – Go to question 34	
	53.	AST (SGOT) : •	□ U/L □ µkat/L
54.	ALT (SGPT)	
	•	nown – Go to question 55	
		nknown – Go to question 56	
		7	
	55.	ALT (SGPT): •	🗆 U/L
			□ μkat/L
Cardi	iac Ass	essments	
56.	Was a	an echocardiogram performed?	
	□ Ye	es – Go to question 57	
		o – Go to question 63	
	□ Ur	nknown – Go to question 63	
	57.	Was tricuspid regurgitant jet velocity (RJV) measured?
		☐ Yes – Go to question 58	
		□ No – Go to question 59	
		58. TRJV: • m/se	
		58. TRJV:•m/se	C
	59.	Was left ventricular ejection fraction (L	VEF) or left ventricular shortening fraction reported?
		☐ Yes – Go to question 60	
		□ No – Go to question 62	
		60. LVEF: %	
CIBMT Copyri	R Form 2	2158 R2 (7 – 14). Form Released 26 July 2024. La 4 The Medical College of Wisconsin, Inc and NMD	ast Updated 26 July 2024. P. All rights reserved.

CIRIN	VIR Center Number: CIBMIR Research ID:
	61. Left ventricular shortening fraction: %
	62. Is documentation being attached? (CIBMTR recommends attaching the echocardiogram report)
	□ Yes
	□ No
63.	Was cardiac MRI performed?
	☐ Yes – Go to question 64
	□ No – Go to question 67
	64. Is there evidence of abnormal cardiac iron deposition based on MRI of the heart?
	□ Yes
	□ No
	65. Cardiac iron T2 imaging
	☐ Known – Go to question 66
	☐ Unknown – Go to question 67
	66. Cardiac iron T2: msec
67.	Was brain natriuretic peptide (BNP) assessed?
	☐ Yes – Go to question 68
	□ No – Go to question 69
	□ Unknown – Go to question 69
	68. BNP:pg/mL
Rena	al Assessments
69.	Was proteinuria detected? (excluding microalbuminuria)
	□ Yes
	□ No
	□ Not done
70.	Serum creatinine
	☐ Known – Go to questions 71
	☐ Unknown – Go to questions 72
	71. Serum creatinine: • mg/dL
CIDMAT	☐ mmol/L ITR Form 2158 R2 (8 – 14). Form Released 26 July 2024. Last Updated 26 July 2024.
	right © 2024 The Medical College of Wisconsin, Inc and NMDP. All rights reserved.

CIBMTR Center Number: CIBMTR Research ID:	_
□ μmol/L	
72. Glomerular filtration rate (GFR) (if multiple, report the most recent tested)	
☐ Known– Go to question 73	
☐ Unknown – Go to question 74	
73. GFR: mL/min/1.73m ² (if the actual value cannot be reported use the Cockcroft- Gault equation to report the calculated value) (for pediatric recipients, use the "Bedside Schwartz" or Cystatin based equation)	C-
Avascular Necrosis	
74. Is there a new area affected by avascular necrosis?	
☐ Yes – Go to question 75	
□ No – Go to question 77	
☐ Unknown – Go to question 77	
75. Specify joint(s) affected (check all that apply)	
 T5. Specify joint(s) affected (check all that apply) □ Hip – Go to question 77 	
☐ Knee – Go to question 77	
☐ Shoulder – Go to question 77	
□ Other – Go to question 76	
76. Specify other:	
Other Symptoms	
Answer the following questions since date of last report.	
77. Have chronic leg ulcers developed?	
□ Yes	
□ No	
□ Unknown	
Additional Iron Overload Assessments	
78. Serum iron	
☐ Known – Go to questions 79	
☐ Unknown – Go to questions 80	
CIBMTR Form 2158 R2 (9 – 14). Form Released 26 July 2024. Last Updated 26 July 2024. Copyright © 2024 The Medical College of Wisconsin, Inc and NMDP. All rights reserved.	

CIBM	ITR Center Number: CIBMTR Research ID:
	79. Serum iron: μg/dL
	□ μmol/L
80.	Total iron binding capacity (TIBC)
	☐ Known – Go to question 81
	☐ Unknown – Go to question 82
	81. TIBC: Φ
	□ μmol/L
82.	Serum ferritin
	☐ Known – Go to questions 83
	☐ Unknown – Go to questions 84
	83. Serum ferritin: ng/mL (μg/L)
84.	Soluble transferrin receptor (sTfR)
	☐ Known – Go to question 85
	☐ Unknown – Go to question 87
	85. sTfR: • mg/L
	86. Date sample drawn: Date estimated
	YYYY MM DD
0.7	
87.	Erythropoietin (EPO) level
	☐ Known – Go to question 88
	□ Unknown – Go to question 90
	88. EPO level: IU/L
	89. Date sample drawn:
	YYYY MM DD
90.	Serum hepcidin level:
	☐ Known – Go to question 91
	☐ Unknown – Go to question 93
	91. Serum hepcidin level: mg/mL (μg/L)

CIBN	ITR C	enter Number:	c	IBMTR Rese	arch ID:	
	92.	Date sample drawn:			DD	□ Date estimated
Addi	tional	Hematologic Labs				
71001						
93.	Retic	ulocyte count				
		Known – Go to question	94			
	□ (Jnknown – Go to questic	on 96			
	94.	Reticulocyte count:	·•	x 10	——	cells/µL
	95.	Date sample drawn:			DD	□ Date estimated
96.		ate dehydrogenase (LDH)				
		nown – Go to question 9				
	□ U	nknown – Go to questioi	1 99			
	97.	LDH:	•	⊐ U/L		
				□ µkat/L		
	98.	Upper limit of normal fo	r your institution	:		•
99.	Hapt	toglobin				
		nown – Go to question 1	00			
		nknown – Go to questio i				
	100.	Haptoglobin:	•-		dL	
				□ g/L		
	101.	Lower limit of normal fo	r vour institution			
		Lower mint of normal ic	i your institution	·		
Exist	ting Or	gan Impairments				
Copy	y and o	complete 102 - 113 to re	port multiple im	npairment		
102.	Spec	cify organ impairments or	disorders develo	pped		
	•	menorrhea– <i>Go to quest</i>				
		ardiomyopathy– Go to qι				
	□С	holelithiasis– <i>Go to ques</i>	tion 103			
	□ G	rowth hormone deficiency	/ short stature -	- Go to ques	tion 103	
CIBM [*] Copyr	TR Form	2158 R2 (11 – 14). Form Relea 24 The Medical College of Wisc	ased 26 July 2024. La onsin, Inc and NMDF	ast Updated 26 J P. All rights rese	luly 2024. rved.	

CIBMTR Cei	nter Number: CIBMTR Research ID:
□ Ну	persplenism– <i>Go to question 103</i>
□ Ну	pothyroidism requiring replacement therapy – <i>Go to question 103</i>
□ Os	teopathies (porosis, penia) – <i>Go to question 103 & 104</i>
□ Pu	lmonary hypertension– <i>Go to question 103</i>
□ Re	tinal changes – <i>Go to question 103</i>
☐ Th	rombosis – Go to question 103
□ No	ne - Go to question 114
103.	Was this organ impairment previously reported?
	□ Yes – Go to question 105
	□ No – Go to question 104
104.	Date of diagnosis: Date estimated
	YYYY MM DD
105.	Method used to assess osteopathies (report the most recent Z or T-score available; Z-scores are used in patients younger than or equal to 20 and T-score in patients older than 20) (check all that apply) □ Dual-energy X-ray absorptiometry (DEXA) scan – <i>Go to question 106</i> □ Quantitative CT– <i>Go to question 110</i> □ Unknown - <i>Go to question 114</i>
	106. DEXA scan vertebral
	☐ Known – Go to question 107
	☐ Unknown – Go to question 108
	107. Z or T– score: □ Negative value
	108. DEXA scan hip ☐ Known – Go to question 109 ☐ Unknown – Go to question 110
	109. Z or T – score: □ Negative value
	110. Quantitative CT vertebral ☐ Known – Go to question 111 ☐ Unknown – Go to question 112
	111 7 or T– score: □ Negative value

CIBMTR (Center Nu	umber: CIBMTR Research ID:					
	112.	Quantitative CT hip					
		☐ Known – Go to question 113					
		☐ Unknown – Go to question 114					
		113. Z or T – score: □ Negative value					
Copy and	d comple	te 102 - 113 to report multiple impairment					
Disease N	l lodifying	Therapies					
	Yes – G	te modifying therapies given? <i>(excludes blood transfusions)</i> to to question 115 to question 122					
	Unknow	n - Go to question 122					
lf tl	here is m	ore than one therapy given copy questions 115- 121 for each therapy.					
11	115. Specify the disease modifying therapy (check all that apply)						
		Hydroxyurea – <i>Go to question 117</i>					
		_uspatercept – Go to question 117					
		Other – Go to question 116					
	116.	Specify other:					
11	7. Was	the date therapy started previously reported?					
		Yes – Go to question 120					
		No – Go to question 118					
	118.	Date therapy started					
		☐ Known - Go to question 119					
		□ Unknown – Go to question 120					
		119. Date therapy started: Date estimated YYYY MM DD					
	120.	Date therapy stopped					
		☐ Known – Go to question 121					
		☐ Unknown - Go to question 122 ☐ Not applicable (still receiving therapy) - Go to question 122					

CIBM	ITR Center Number:	CIBMTR Research ID:						
	121. Date therapy stopped:	:			□ Date estimated			
		YYYY	MM	DD				
Marrow Evaluation								
Complete question 122 for gene therapy infusions only								
122.	22. Was a marrow aspirate and / or biopsy performed?							
	☐ Yes - Also complete Laboratory Studies Form 3502 and Marrow Surveillance Form 3506							
	□ No							
	☐ Unknown							